reboxetine has been researched along with risperidone in 3 studies
Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (risperidone) | Trials (risperidone) | Recent Studies (post-2010) (risperidone) |
---|---|---|---|---|---|
626 | 193 | 184 | 6,924 | 1,505 | 2,477 |
Protein | Taxonomy | reboxetine (IC50) | risperidone (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.015 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0027 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0097 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 5.2734 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 4.1901 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.0167 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0991 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0096 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.799 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.479 | |
Histamine H2 receptor | Homo sapiens (human) | 1.483 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.01 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0016 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0057 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.799 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0027 | |
5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.0015 | |
Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.0105 | |
5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.0015 | |
Histamine H1 receptor | Homo sapiens (human) | 0.4515 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.024 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.023 | |
D(2) dopamine receptor | Mus musculus (house mouse) | 0.023 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0154 | |
5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.0015 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6303 | |
5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.43 | |
Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 4.1901 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.6 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ancione, M; Avenoso, A; Levita, A; Madia, A; Scordo, MG; Spina, E | 1 |
Baghai, TC; Laenger, A; Leicht, G; Lindhaus, S; Rupprecht, R; Schule, C | 1 |
Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J | 1 |
1 trial(s) available for reboxetine and risperidone
Article | Year |
---|---|
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Citalopram; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Olanzapine; Psychiatric Status Rating Scales; Reboxetine; Risperidone; Schizophrenia; Schizophrenic Psychology | 2014 |
2 other study(ies) available for reboxetine and risperidone
Article | Year |
---|---|
No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Clozapine; Drug Interactions; Female; Humans; Male; Middle Aged; Morpholines; Reboxetine; Risperidone | 2001 |
Electroconvulsive therapy in a patient with concomitant depression and charcot-marie-tooth disease.
Topics: Aged; Charcot-Marie-Tooth Disease; Combined Modality Therapy; Comorbidity; Contraindications; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Male; Morpholines; Personality Inventory; Reboxetine; Risperidone; Treatment Outcome | 2008 |